Investigating the Utility of Demyelination Tracer [18F]3F4AP in Controls and Multiple Sclerosis Subjects

Recruiting Phase 1 Interventional Study
Multiple Sclerosis
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 65
Sex
Any
Trial phase
Phase 1
Study type
Interventional
Purpose
Basic Science
Participants needed
60 (estimated)
Sponsor
Massachusetts General Hospital · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Our overall objective is to obtain an initial assessment of the potential value of using \[18F\]3F4AP for imaging demyelinating diseases such as multiple sclerosis: * Aim 1) Assess the safety of \[18F\]3F4AP in healthy volunteers and subjects with multiple sclerosis (MS). Hypothesis 1: Administration of \[18F\]3F4AP will result in no changes in vitals or other adverse events. * Aim 2) Assess the …
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Subjects must be ≥18 and \<65 years of age; * Able to understand and provide informed consent prior to study procedures Exclusion Criteria: * Subjects with known structural brain disease (e.g. brain tumor or stroke); * Any contraindication to MRI and/or PET, including: * …
Contacts

Pedro Brugarolas, PhD

(617) 643-4574

pbrugarolas@mgh.harvard.edu

CONTACT